Treatment Options for Dementia with Lewy Bodies: A Network Meta-Analysis of Randomised Control Trials.

ABSTRACT:

Introduction

Dementia with Lewy bodies (DLB) is the third most common type of dementia after Alzheimer's disease (AD) and vascular dementia. Treatment is targeted at specific disease manifestations/symptoms. While donepezil is approved for the treatment of DLB in Japan, to date no other treatment has been approved for this indication anywhere in the world. Notwithstanding, many of the medications that are approved for AD are widely used in the treatment of DLB with varying degrees of success. Consequently, clinical evidence is limited, and there is a need to understand the comparative efficacy and safety of currently used therapies for DLB. The aim of this study was to conduct a network meta-analysis (NMA) to evaluate the outcomes of the available treatment options based on current

SUBMITTER: Tahami Monfared AA 

PROVIDER: S-EPMC7606367 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature